Advancements in the Management of Pancreatic Cancer: 2015 ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, USA. January 15-17, 2015)
Abstract
No abstract available.
Image: NAPOLI-1 study schema.
Downloads
References
American Cancer Society. Cancer Facts & Figures 2015. Atlanta, Ga: American Cancer Society; 2015.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-25. [PMID: 21561347]
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691-703. [PMID: 24131140]
Dalgleish AG, The IMAGE I Trial Investigators. A multicenter randomized, open-label, proof-of-concept, phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer. J Clin Oncol 2015 (suppl 3; abstr 336). Abstract available online at http://meetinglibrary.asco.org/content/139999-158.
Elia A, Lincoln L, Brunet LR, Hagemann T. Treatment with IMM-101 induces protective CD8+ T cell responses in clinically relevant models of pancreatic cancer. J Immunother Cancer 2013; (Suppl 1):215. [PMCID: PMC3991081]
Whiting C, Lutz E, Nair N, Chang S, Lemmens E, Chen SY et al. Phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer: Clinical update on long term survival and biomarker correlates to overall survival. J Clin Oncol 2015; (suppl 3; abstr 261). Abstract available online at http://meetinglibrary.asco.org/content/140513-158.
Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 2008; 7:286-96. [PMID: 18281514]
Zhang S, Yong LK, Li D, Cubas R, Chen C, Yao Q. Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS- regulatory T cells. PLoS One 2013; 8:2013. [PMID: 23874581]
Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM et al. Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer. J Clin Oncol 2015; (suppl 3; abstr 359). Abstract available online at http://meetinglibrary.asco.org/content/140629-158.
Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res 2012; 18:4266-76. [PMID: 22896693]
Clinicaltrials.gov. History of NCT01839487. PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer. Available online at https://clinicaltrials.gov/archive/NCT01839487.
Chen LT, Von Hoff DD, Li CP, Wang-Gillam A, Bodoky G, Dean AP et al. Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. J Clin Oncol 2015; (suppl 3; abstr 234). Abstract available online at http://meetinglibrary.asco.org/content/140017-158.
Ettrich TJ, Perkhofer L, Kaechele V, Berger AW, Guethle M, Muche R et al. A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas—Final results. J Clin Oncol 2015; (suppl 3; abstr 352). Abstract available online at http://meetinglibrary.asco.org/content/139392-158.
Mitsunaga S, Umemoto K, Watanabe K, Okuyama H, Takahasi H, Ohno I et al. S100P tumor-marker response to chemotherapy in patients with advanced pancreatic cancer. J Clin Oncol 2015; (suppl 3; abstr 265). Abstract available online at http://meetinglibrary.asco.org/content/140215-158.
Dakhel S, Padilla L, Adan J, Masa M, Martinez JM, Roque L et al. S100P antibody-mediated therapy as a new promising strategy for the treatment of pancreatic cancer. Oncogenesis 2014; 3:e92. [PMID: 24637492]
Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM et al. Exploratory biomarker results from early investigation of PEGPH20 in combination with gemcitabine (Gem) in patients with pancreatic cancer (PDA). J Clin Oncol 2015; (suppl 3; abstr 300). Abstract available online at http://meetinglibrary.asco.org/content/140593-158.
Van Cutsem E, Hidalgo M, Bazin I, Canon JC, Poddubskaya E, et al. Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer. J Clin Oncol 2015; (suppl 3; abstr 344). Abstract available online at http://meetinglibrary.asco.org/content/139531-158.
Mahipal A, Springett gm, Burke N, Bertels B, Wapinsky G, et al. Phase I trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. J Clin Oncol 2015; (suppl 3; abstr 467). Abstract available online at http://meetinglibrary.asco.org/content/139221-158
Beg MS, Morse M, Patel SP, Mavroukakis S, Beatson MA, et al. A phase I/II multicenter study of the chimeric monoclonal antibody NEO102 (NPC-1C) in adults with refractory pancreatic (PC) and colorectal cancer (CC). J Clin Oncol 2015; (suppl 3; abstr 467). Abstract available online at http://meetinglibrary.asco.org/content/139964-158.
Copyright (c) 2015 Frank C Jr. Passero, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.